LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$101.71 USD
+3.08 (3.12%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.71 USD
+3.08 (3.12%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $101.68 -0.03 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Zacks News
LeMatire Vascular, 3D Systems, Tesla and Apple highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
LeMatire Vascular, 3D Systems, Tesla and Apple highlighted as Zacks Bull and Bear of the Day
Bull Of The Day: LeMatire Vascular (LMAT)
by Brian Bolan
In a space that is seeing topline contraction, this stock is seeing topline growth, and lots of it!
LeMaitre Vascular (LMAT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
by Zacks Equity Research
Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
by Zacks Equity Research
In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.
Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance
by Zacks Equity Research
Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.
4 Critical Care Device Stocks to Deflect the COVID-19 Curveball
by Debanjana Dey
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
New Strong Buy Stocks for April 8th
by Zacks Equity Research
MDC, NTR, LMAT, CSTR, and MYRG have been added to the Zacks Rank #1 (Strong Buy) List on April 8, 2021.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
LeMaitre (LMAT) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
LeMaitre (LMAT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up
by Zacks Equity Research
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.
Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech
by Zacks Equity Research
Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech
5 Top-Ranked Liquid Stocks To Bet On For Alluring Returns
by Radhika Pujara
Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
by Zacks Equity Research
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech
by Zacks Equity Research
Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech
4 Promising Top-Ranked Liquid Stocks to Boost Your Portfolio
by Radhika Pujara
Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
by Zacks Equity Research
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
Boston Scientific (BSX) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: LeMaitre Vascular
by Zacks Equity Research
LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
LeMaitre Vascular (LMAT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?